T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
Murphy USA
MUSA
$10.4B
| $3.24M | ﹤0.01% |
66,355
-9,400
| -12% | -$436K |
|
1502
Genpact
G
$5.78B
| $3.18M | ﹤0.01% |
181,300
+20,300
| +13% | +$347K |
|
|
BEAV
1503
DELISTED
B/E Aerospace Inc
BEAV
| $3.18M | ﹤0.01% |
47,437
+7,601
| +19% | +$506K |
|
|
CBI
1504
DELISTED
Chicago Bridge & Iron Nv
CBI
| $3.1M | ﹤0.01% |
45,428
+9,846
| +28% | +$783K |
|
|
XOXO
1505
DELISTED
Xo Group Inc
XOXO
| $3.09M | ﹤0.01% |
252,500
-91,900
| -27% | -$1.02M |
|
1506
Realty Income
O
$59.6B
| $3.04M | ﹤0.01% |
70,514
+8,174
| +13% | +$342K |
|
1507
Miller Industries
MLR
$643M
| $3.02M | ﹤0.01% |
146,710
+700
| +0.5% | +$13.8K |
|
1508
SiriusXM
SIRI
$9.43B
| $3M | ﹤0.01% |
86,747
-1,009
| -1% | -$32.8K |
|
|
VER
1509
DELISTED
VEREIT, Inc.
VER
| $2.99M | ﹤0.01% |
47,753
+8,282
| +21% | +$532K |
|
1510
AGNC Investment
AGNC
$13B
| $2.98M | ﹤0.01% |
127,310
+8,183
| +7% | +$188K |
|
1511
American Water Works
AWK
$26.8B
| $2.97M | ﹤0.01% |
60,100
+7,800
| +15% | +$367K |
|
|
FUEL
1512
DELISTED
Rocket Fuel Inc.
FUEL
| $2.96M | ﹤0.01% |
95,071
+23,688
| +33% | +$703K |
|
|
AUXL
1513
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $2.96M | ﹤0.01% |
147,300
+18,200
| +14% | +$417K |
|
1514
Crawford & Co Class A
CRD.A
$627M
| $2.94M | ﹤0.01% |
362,641
+29,211
| +9% | +$256K |
|
1515
MediWound
MDWD
$174M
| $2.91M | ﹤0.01% |
+36,502
| New | +$2.97M |
|
1516
Steel Dynamics
STLD
$37.7B
| $2.88M | ﹤0.01% |
160,228
+41,400
| +35% | +$744K |
|
1517
Signet Jewelers
SIG
$3.59B
| $2.88M | ﹤0.01% |
26,000
-5,100
| -16% | -$531K |
|
1518
Heartland Express
HTLD
$979M
| $2.85M | ﹤0.01% |
133,719
-3,880
| -3% | -$84K |
|
|
GXP
1519
DELISTED
Great Plains Energy Incorporated
GXP
| $2.83M | ﹤0.01% |
105,198
+6,900
| +7% | +$180K |
|
1520
Rio Tinto
RIO
$160B
| $2.82M | ﹤0.01% |
51,890
| – | – |
|
|
UTX.PRA
1521
DELISTED
UNITED TECHNOLOGIES CORP CORP UNIT (DE)
UTX.PRA
| $2.76M | ﹤0.01% |
42,100
+3,950
| +10% | +$260K |
|
|
HCAP
1522
DELISTED
Harvest Capital Credit Corporation
HCAP
| $2.74M | ﹤0.01% |
184,600
+700
| +0.4% | +$10.1K |
|
|
RGLS
1523
DELISTED
Regulus Therapeutics
RGLS
| $2.71M | ﹤0.01% |
2,810
+5
| +0.2% | +$4.29K |
|
|
GES
1524
DELISTED
Guess Inc
GES
| $2.7M | ﹤0.01% |
99,920
+8,000
| +9% | +$217K |
|
|
AEGR
1525
DELISTED
Aegerion Pharmaceuticals
AEGR
| $2.69M | ﹤0.01% |
83,900
-3,355,753
| -98% | -$125M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.